At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CGON CG Oncology Inc.
Trading 01-21 14:23:20 EST
56.27
+1.58
+2.89%
High57.83Low53.89Vol1.86M
Open54.98D1 Closing54.69Amplitude7.20%
Mkt Cap4.54BTradable Cap3.68BTotal Shares80.67M
T/O105.87MT/O Rate2.85%Tradable Shares65.44M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

CG Oncology Is Maintained at Outperform by RBC Capital
Dow Jones  ·  01-21 22:55
CG Oncology Is Maintained at Outperform by RBC Capital
RBC Raises Price Target on CG Oncology to $73 From $61, Keeps Outperform, Speculative Risk
MT Newswires Live  ·  01-21 19:59
RBC Raises Price Target on CG Oncology to $73 From $61, Keeps Outperform, Speculative Risk
CG Oncology price target raised to $73 from $61 at RBC Capital
TIPRANKS  ·  01-21 19:35
CG Oncology price target raised to $73 from $61 at RBC Capital
CG Oncology Is Maintained at Overweight by Piper Sandler
Dow Jones  ·  01-17
CG Oncology Is Maintained at Overweight by Piper Sandler
CG Oncology price target raised to $70 from $55 at Piper Sandler
TIPRANKS  ·  01-16
CG Oncology price target raised to $70 from $55 at Piper Sandler
CG Oncology Expands At-The-Market Equity Offering Capacity
TIPRANKS  ·  01-14
CG Oncology Expands At-The-Market Equity Offering Capacity
CG Oncology Inc Files for Offering of up to $550 Mln Common Stock - SEC Filing
THOMSON REUTERS  ·  01-14
CG Oncology Inc Files for Offering of up to $550 Mln Common Stock - SEC Filing
CG Oncology Director James Mulay Reports Disposal of Common Shares
Reuters  ·  01-14
CG Oncology Director James Mulay Reports Disposal of Common Shares
CG Oncology Is Maintained at Buy by Truist Securities
Dow Jones  ·  01-13
CG Oncology Is Maintained at Buy by Truist Securities
Wedbush Raises Price Target on CG Oncology to $77 From $70, Keeps Outperform Rating
MT Newswires Live  ·  01-12
Wedbush Raises Price Target on CG Oncology to $77 From $70, Keeps Outperform Rating
Assessing CG Oncology (CGON) Valuation After Strong Recent Share Price Momentum
Simply Wall St.  ·  01-11
Assessing CG Oncology (CGON) Valuation After Strong Recent Share Price Momentum
Accelerated Creto Trajectory in NMIBC Drives Earlier Data, De-Risked Commercialization, and Higher $66 Target Supporting Buy Rating on CG Oncology
TIPRANKS  ·  01-10
Accelerated Creto Trajectory in NMIBC Drives Earlier Data, De-Risked Commercialization, and Higher $66 Target Supporting Buy Rating on CG Oncology
CG Oncology price target raised to $66 from $62 at Truist
TIPRANKS  ·  01-10
CG Oncology price target raised to $66 from $62 at Truist
CG Oncology price target raised to $93 from $89 at Morgan Stanley
TIPRANKS  ·  01-10
CG Oncology price target raised to $93 from $89 at Morgan Stanley
CG Oncology Up Over 27%, on Track for Record High Close and Record Percent Increase -- Data Talk
Dow Jones  ·  01-10
CG Oncology Up Over 27%, on Track for Record High Close and Record Percent Increase -- Data Talk
Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January
Benzinga  ·  01-10
Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January
CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday
Benzinga_recent_news  ·  01-10
CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday
CG Oncology: Early PIVOT-006 Readout, Strengthened Creto Outlook, and 2026 Catalyst Wave Support Buy Rating and Higher $85 Target
TIPRANKS  ·  01-10
CG Oncology: Early PIVOT-006 Readout, Strengthened Creto Outlook, and 2026 Catalyst Wave Support Buy Rating and Higher $85 Target
CG Oncology rises 16.0%
TIPRANKS  ·  01-09
CG Oncology rises 16.0%
CG Oncology Accelerates Phase 3 Bladder Cancer Trial Timeline
TIPRANKS  ·  01-09
CG Oncology Accelerates Phase 3 Bladder Cancer Trial Timeline
No data available

Introduction

Company Name.
CG Oncology Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--